Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
- Written by PR Newswire
ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.
Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep.
BNC210 was well-tolerated with a safety profile supporting chronic administration.
Company plans to...